Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis

Nymox Pharmaceutical logo

About Nymox Pharmaceutical Stock (NASDAQ:NYMX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.19
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

Nymox Announces Filing of Annual Report
Nymox Annual Report
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
Nymox December 27 Message to Shareholders
See More Headlines

NYMX Stock Analysis - Frequently Asked Questions

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company earned $0.08 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Biocept (BIOC), TherapeuticsMD (TXMD) and CTI BioPharma (CTIC).

Company Calendar

Last Earnings
11/14/2014
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NYMX
CIK
1018735
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.58 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,589.50%
Return on Assets
-117.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,510,000
Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NYMX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners